As TAVI expands to younger and healthier patients, valve durability has become an increasingly important consideration. However, the optimal antithrombotic strategy to support long-term valve function remains unclear. This trial compared antiplatelet monotherapy with NOAC monotherapy to help address this unmet need.

In this episode, Deepak L. Bhatt MD, MPH, MBA, FACC and Øyvind H. Lie, MD, PhD, MSc examine the results of "ACASA-TAVI: Antithrombotic therapy after TAVI".

Related References:

1. Dodgson CS, Herstad J, Kløve SF, et al. Anticoagulation Monotherapy vs Antiplatelet Monotherapy After Transcatheter Aortic Valve Implant: The ACASA-TAVI Randomized Clinical Trial. JAMA. Published online August 30, 2026. doi:10.1001/jama.2026.17036